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Abstract
Background: Serious bacterial infections are a major source of morbidity and mortality in HIV-infected children. The
spectrum of disease is wide, and responsible organisms vary according to setting. The use of antibiotic prophylaxis and the
emergence of multi-drug resistant bacteria necessitate examination of responsible organisms and their antibiotic
susceptibility.
Methodology/Principal Findings: A retrospective cohort study of all HIV-positive pediatric admissions at an urban public
sector hospital in Cape Town between January 2002 and June 2006 was conducted. Children between the ages of one
month and nine years with laboratory confirmed HIV status, serious bacterial infection, and a hospital length of stay of 5
days or more, were eligible for inclusion. Organisms isolated from blood, urine, and cerebral spinal fluid cultures and their
antimicrobial susceptibility were examined, and compared according to timing of isolation to distinguish nosocomial versus
community-acquired. One hundred and forty-one children were identified (median age 1.2 years), 39% of whom were on
antiretrovirals started before or during this hospitalization. Bacterial infections involved all organ systems, however
pneumonia was most common (67%). S. pneumoniae and S. aureus were the most common gram positive and K.
pneumoniae was the most common gram negative organism. K pneumoniae isolates were resistant to many first and second
line antibiotics, and were all considered nosocomial. All S. aureus isolates were methicillin resistant, some of which were
community-acquired.
Conclusions/Significance: Bacterial infections are an important source of co-morbidity in HIV-infected children in resource-
limited settings. Clinicians should have a low threshold to initiate antibiotics in children requiring hospitalization. Broad-
spectrum antibiotics should be used judiciously. Clinicians caring for HIV-infected children should be cognizant of the most
common organisms affecting such children, and of their local antimicrobial susceptibilities, when treating empirically for
serious bacterial infections.
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Introduction
Bacterial infections are a major source of morbidity and
mortality in HIV- infected children, causing . a wide spectrum of
diseases, many of which are included in the WHO and CDC
staging systems[1,2] In an early USA study predating both
trimethoprim-sulfamethoxazole (TMP-SMX) and antiretroviral
therapy (ART)[3], there were 160 episodes of minor and 48
serious bacterial infections (SBI) per 100 patient-years in HIV-
infected children, demonstrating the extremely high burden of
bacterial morbidity. A similar study performed after the introduc-
tion of TMP-SMX and zidovudine monotherapy documented a
two-year SBI rate of 45% among children receiving TMP-
SMX.[4]. In a randomized controlled trial of TMP-SMX
prophylaxis for HIV-infected children in Zambia, the SBI
admission rate was 19 per 100 child-years in the TMP-SMX
group and 29 in the placebo group (P= 0.09), and the cumulative
two-year probability of dying in hospital from SBI (predominantly
pneumonia) was 7% on TMP-SMX and 12% on placebo
(P= 0.08).[5] Thus, data from varied settings documented high
rates of SBI in children and a protective effect of TMP-SMX.
Since the widespread availability of antiretroviral therapy (ART),
there has been a marked decrease in the morbidity and mortality of
bacterial infections in both resource rich and resource limited
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settings [6], [7]. In the USA, pneumonia is still the most common
bacterial infection in HIV-infected children on ART, however, in
comparison with the pr-ART era, the incidence has decreased from
11 to 2 events per 100 person years.[8] In a Californian cohort,
bacterial infections accounted for 60 hospitalizations for 64 children
in 1994, versus only 8 for 101 children in 2001.[9] The
hospitalization rate for SBI was only 14.2 per 100 person years
for a Thai cohort of children on ART.[10] Nevertheless, bacterial
infections remained the most common reason for hospitalization.
HIV-infected children have a greater risk of bacterial infections
than their HIV-negative counterparts[11], and these infections are
more invasive, more likely to disseminate, and have worse outcome
in HIV-infected children.[11–13] Also, HIV-infected children often
have multiple diagnoses and polymicrobial infections.[11,12] All
organ systems can be involved by bacterial infections, and
concomitant bacteraemia is common. Abscess formation in internal
organs and skin can also occur. Otitis media (OM), acute sinusitis
and mastoiditis are also common. By far the most frequent cause of
bacterial morbidity in all HIV-infected children is pneumonia, both
with and without TMP-SMX prophylaxis.[5]
The emergence of antimicrobial resistant organisms is a global
problem, not restricted to children with HIV. However, the
widespread use of TMP-SMX for prophylaxis may exacerbate
antimicrobial resistance. In a South African study, only four of 26
S. pneumoniae from HIV-infected children with community
acquired pneumonia were sensitive to TMP-SMX.[11] Resistance
was unaffected by TMP-SMX prophylaxis, arguing that resistance
may be firmly established in the community. The antimicrobial
resistance patterns from blood cultures from HIV infected and
uninfected children have been compared in only a few settings.
The resistance of both S. pneumoniae and S. aureus to TMP-SMX was
significantly higher in the HIV-infected group’s isolates in Soweto
[14]. In three African studies, almost 15% of the isolates from
HIV-infected children were multiply resistant E. coli or Methicillin
resistant staphylococcus aureus (MRSA). [14–16] However, in the
Ugandan children, organisms from HIV-infected children were
either more sensitive or had the same profile as uninfected
children.[16] Therefore it is unclear how widespread antimicrobial
resistance is in HIV-infected children.
Methods
Objectives
We sought to evaluate the spectrum of bacterial infection,
causative organisms, and antibiotic resistance patterns of an
inpatient cohort of HIV-infected children.
Participants
We conducted a retrospective cohort study of all HIV-positive
pediatric admissions to a Pediatric ward in an urban public sector
hospital in Cape Town between January 2002 and June 2006.
Over 50% of all admissions are HIV-infected. The referral
population is a largely black African population living in rapidly
growing settlements with residents of predominantly low socio-
economic status. Data were collected from paper charts and
computer records. Where more than one hospitalization per
patient occurred, only the first was examined.
Children between one month and nine years of age with
laboratory confirmed HIV-infection, SBI and hospitalization for 5
or more days, were eligible for inclusion.
Description of investigations
The following were considered SBI: bacterial sepsis, bacterial
pneumonia, urinary tract infection, and/or meningitis. For
bacterial sepsis, children had organisms identified on blood
culture. Diagnosis of bacterial pneumonia was made by clinical
findings, laboratory results including high white blood cell count
with neutrophil predominance, lobar consolidation on chest
radiograph, and blood cultures when available. For meningitis,
either an organism was isolated from cerebrospinal fluid or the
chemistry and cell counts were suggestive of bacterial infection.
Coagulase negative staphylococcus only included as a pathogen if
isolated from more than one culture or from a patient with
indwelling invasive lines. All S. aureus isolates were considered
pathogenic, as the patients were ill. An infection was considered
community acquired if symptomatic at admission or if cultures
taken at or before 48 hours after admission were positive. If
Table 1. Demographics and spectrum of serious bacterial
disease in hospitalized children with HIV.
Characteristic n (%)
Gender
Males 76 (54)
Females 65 (46)
On ART 55 (39)
On TB medication 39 (28)
Mortality 13 (9)
Age at admission (yrs) 1.2 (0.5–2.34)
Median (IQR)
Weight at admission (kg) 6.7 (4.7–9.6)
Median (IQR)
Temp. at admission (uC) 37.3 (36.5–38.3)
Median (IQR)
Birth weight (kg) 2.8 (2.8–3.0)
Mean (95% CI)
Hemoglobin on admission 9.1 (8.1–10.3)
Median (IQR)
Concomitant Diagnoses
TB 40 (28)
TB meningitis 2 (1)
Gastroenteritis 54 (38)
PEM 16 (11)
Fungal sepsis 4 (2.3)
Failure to thrive 29 (21)
Bacterial Infections 40 (28)
Bacterial sepsis 74 (52)
Pneumonia 95 (67)
% Bacteremic pneumonia 50
Bacterial meningitis 4 (3)
% Bacteremic meningitis 50
Urinary tract infection 15 (11)
% Bacteremic UTI 87
Skin or soft tissue, including abscess 2 (1.5)
Osteomyelitis or septic arthritis 1 (0.7)
ART–antiretroviral therapy, TB–Tuberculosis, PEM-Protein energy malnutrition,
IQR–Interquartile range.
doi:10.1371/journal.pone.0003260.t001
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positive cultures or new symptoms appeared after 48 hours, the
infection was considered nosocomial or hospital acquired [17].
Clinical specimens submitted for bacterial culture were
inoculated into appropriate media depending on the nature of
the specimen. Organisms were identified by standard biochemical
and/or serological methods. Antimicrobial susceptibility testing
was done by the Kirby-Bauer disc diffusion technique, and MICs
(if necessary) were performed using E-tests. Susceptibilities were
not available for all specimens from 2002–2003. Therefore,
susceptibilities represent more recent specimens.
Ethics
Approval for this study was obtained from the University of
Cape Town Faculty of Health Sciences Research Ethics
Committee. Exemption from informed consent was granted as
this was a retrospective study with no identifying data.
Results
Cohort Demographics
One hundred and forty-one children met inclusion criteria. The
median age was 1.2 years (IQR 0.5–2.3) and 65 (46%) were female
(table 1). The median weight on admission was 6.7 kg (IQR 4.7–
9.6)), 16 (11.4%) with a diagnosis of marasmus and a further 27
(19%) labeled as failure to thrive.
Approximately one third of children received ART(n= 55).
However, the median time on ART was only 6 days (IQR -8–35),
and many were started during this hospitalization. There were 40
children on tuberculosis treatment; some children were receiving
both ART and TB treatment (n = 16; 11.3%). The median CD4
percentage was 17.2% (IQR 9.7–22.7), with a median absolute
CD4 count of 509 cells/mm3 (IQR 244–759). The median
hospital length of stay was 13 days (IQR 6–34 days). There were
13 deaths in hospital with the remainder being discharged.
Spectrum of Disease
A lower respiratory tract infection was diagnosed in 95 (67%) of
the children, while 74 (53%) had bacterial sepsis. The most
prevalent bacterial infections in this cohort of hospitalized children
were pneumonia and sepsis (Table 1). However, most other organ
systems were affected, including the central nervous system
(meningitis), lung, mastoid, bone and joints. A high proportion
of patients with pneumonia, meningitis, and urinary tract infection
had concomitant bacteremia. Mycobacterium tuberculosis was a
frequent concomitant infection. Eight deaths had dual diagnoses
of sepsis and pneumonia, and one had both sepsis and a UTI.
Responsible Organisms
The relative frequencies of specific bacterial isolates from blood,
urine and CSF cultures of HIV-infected children are shown in
table 2 (excluding mycobacteria). The most common pathogen
isolated from blood was S. pneumoniae followed by S aureus. The
most common gram negative organism was K. pneumoniae. All K.
pneumoniae isolates were from blood cultures taken more than two
days into the admission, implying a nosocomial origin. In contrast,
all but two S pneumoniae from blood culture were within two days of
admission, therefore probably community acquired. The organ-
isms most frequently present when the outcome was fatal were S
aureus (n = 3, all MRSA), Coagulase negative staphylococcus (n = 3)
and K pneumoniae (n = 3). Five of the 13 children who died grew
multiple pathogenic organisms in blood or urine.
Susceptibility Patterns
The antimicrobial susceptibility patterns of each of the more
prevalent organisms are shown in table 3. S. pneumoniae and H.
influenza isolates were generally highly susceptible, whereas the
majority of the K. pneumoniae isolates, most likely nosocomial, were
highly resistant. All K. pneumoniae isolates were extended spectrum
beta-lactamase producing; the only single antibiotic to which all K.
Table 2. Bacterial isolates from hospitalized HIV-infected children with serious bacterial infections*
Blood n=128 (%1) Urine n=21 (%2) CSF n=36 (%2)
N (%) assumed nosocomial
(.48 hours)3
S. pneumoniae 21 (16) 1 (2.8) 2/22 (9%)
S. aureus 14 (11) 9/14 (64%)
Coagulase negative staphylococcus4 4 (3) 4/4 (100%)
E. coli 5 (4) 5 (24) 7/10 (70%)
K. pneumoniae 11 (9) 2 (9.5) 13/13 (100%)
Hemophilus spps 8 (7) 1 (2.8) 1/9 (11%)
S. typhi 1 (1) 0
Non typhoid salmonella 9 (7) 1 (4.8) 7/10 (70%)
S. milleri 1 (1) 1 (100%)
Enterococcus faecalis 4 (3) 2 (9.5) 5/6 (83%)
Enterococcus faecium 1 (1) 1 (100%)
Enterobacter species 6 (4) 4/6 (67%)
P. aeruginosa 1 (1) 1 (4.8) 0
Acinetobacter 4 (3) 3/4 (75%)
1Percent of positive cultures, including fungal and mixed or skin flora
2Percent of all cultures sent. Urine cultures were not done if urine dipstick was normal unless suspicion was high.
3The proportion of nosocomial infections presented here reflects that from children hospitalized for five days or longer, and not necessarily the proportion of
nosocomial infections from hospitalizations of all HIV-infected children.
4Coagulase negative staphylococcus only included as a pathogen if isolated from more than one culture or with indwelling invasive lines.
doi:10.1371/journal.pone.0003260.t002
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pneumoniae isolates were susceptible was Meropenem. S. aureus
whether community-acquired or nosocomial, was often resistant to
TMP-SMX, and clindamycin, both frequently used antibiotics for
resistant staphylococci. . Although community-acquired non-
typhoid salmonella (NTS) were susceptible to first-line antibiotics
such as ampicillin, the more frequently hospital-acquired organ-
isms were more resistant. MRSA was isolated from a third of the
blood cultures of children who died, as was K. pneumoniae, therefore
resistant organisms were possibly responsible for a relatively high
proportion of the mortality, and appropriate empiric therapy was
not used.
Discussion
In this cohort of hospitalized HIV-infected children, pneumonia
was the most common SBI resulting in hospitalization. There was
frequent coincident bacteremia. This is consistent with other HIV-
infected pediatric cohorts described from both developing and
developed settings[5,8]. The relative prevalence of most bacterial
pathogens is similar to that of HIV-uninfected children. In a large
Kenyan study S. pneumoniae, H. influenzae, NTS, and E. coli were
more common in HIV-infected children [18]. These organisms
were commonly seen in malnourished children in the pre-HIV
era. S. pneumoniae is the most common organism in other cohorts,
with S. aureus, Salmonella species, and Enterobacteriaceae occurring
frequently [4,11,14,15]. P. aeruginosa is also seen occasionally. The
proportion of H influenzae is influenced by the introduction of the
H. influenzae type B (Hib) vaccine, in 1999 in South Africa.
Bacteria that were assumed to be predominantly community
acquired were generally susceptible to first line or narrow spectrum
antibiotics (those that target generally only one class of bacteria).
This included the S. pneumoniae isolates. In other settings, multi-drug
resistant S. pneumoniae were increasing in frequency before
introduction of the pneumococcal conjugate vaccine [19,20]. In
children with community acquired pneumonias in Soweto, South
Africa, 50% of the S. pneumoniae isolates from the HIV-infected
children were penicillin resistant versus 23% of the HIV-negative
children’s isolates.[14] The community-acquired S. aureus isolates
were, however, all MRSA. The empiric treatment of community
acquired bacterial infections in HIV-infected children in resource
limited settings should bear in mind the antimicrobial susceptibility
patterns of the region. Penicillin and ampicillin are effective against
most penicillin-non-susceptible pneumococcal isolates in the case of
isolated respiratory tract infections. The clinician must consider
viral, fungal, and mycobacterial infections in the differential
diagnosis of bacterial infections and treat accordingly.
The high proportion of K. pneumoniae resistant to third
generation cephalosporin is highly concerning, particularly since
all these infections were acquired after two days in hospital, and
therefore probably hospital-acquired. Highly resistant organisms
have been described from a similar setting [15], and is likely due to
extended spectrum beta lactamase production. Since not all K.
pneumoniae isolates were susceptible to piperacillin-tazobactam or
amikacin, clinicians should consider empiric carbapenems for
suspected hospital-acquired sepsis.
Nosocomial infections are more common in HIV-infected than
in uninfected adults, with the most frequently isolated bacterial
pathogens being S. aureus and P. aeruginosa, a high proportion of
which are methicillin resistant [21]. Nosocomial infections in HIV-
infected adults have a high mortality. There are few data on
nosocomial bacterial infections in HIV-infected children. In a
cohort of children hospitalized with TB, nosocomial infections
were more common in HIV-infected patients, and more frequently
fatal [22]. Although our data do not reflect the overall prevalence
of nosocomial infections in hospitalized HIV-infected children due
to our study design, the data may represent common resistance
patterns of these organisms.
The most effective public health approach to improving
infectious disease burden is vaccination. Effective vaccines are
licensed for Hib and S. pneumoniae. Both are polysaccharide protein
conjugate vaccines. The Hib vaccine is now widely available
including in developing countries. Although the estimated efficacy
of the Hib vaccine is decreased and the risk for vaccine failure
increased in HIV-infected children,[23,24] the introduction of Hib
vaccine into countries with high HIV prevalence has greatly
decreased Hib disease burden.[25] In 2000, a pneumococcal
conjugate vaccine (PCV) was licensed in the USA. Although PCV
is less immunogenic in HIV-infected children than non-infected
children,[26] this also seems to improve in children receiving
ART.[27] A similar 9-valent PCV has been extensively studied in
South Africa, and similar efficacy is seen in these HIV-infected
infants.[28] Unfortunately, PCV is not widely accessible to
children in less resourced countries, and its access should become
a global priority.
These data confirm that pneumonia is the most common SBI in
HIV-infected children, but with a wide spectrum of presentation.
The predominance of MRSA is alarming. The high proportion of
nosocomially acquired highly resistant K. pneumoniae, suggest that
infection control practices should be implemented to avoid the
spread of antibiotic resistance. While overuse of broad-spectrum
antibiotics should be avoided, judicious limited use is indicated for
suspected nosocomial sepsis.
Limitations
The limitations of these data are that they are retrospective and
therefore incomplete. In addition, the isolation of organisms is
dependant on adequate blood volumes and rapid transport to the
microbiology laboratory, both of which may have been limited in
the setting of sick, malnourished children in a resource-limited
hospital. Our findings may not be generalizable to other better
resourced settings such as those with more nursing staff, and less
ward crowding, or where all HIV-infected children are on ART.
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